Kenvue
About the company
Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates in three segments: Self Care, Skin Health and Beauty, and Essential Health. The company offers over-the-counter medicine for cough, cold and allergy, pain care, digestive health, smoking cessation, and eye care, as well as other naturally inspired and self-care products, digital diagnostics, and telemedicine; face and body care, hair, sun, and other care products; oral and baby care, women's health, wound care, and other essential health products; tampons; cosmetics; and vitamins and supplements. It sells its products under the Benadryl, Calpol, Motrin, Nicorette, Rhinocort, Tylenol, Zarbee's Naturals, and Zyrtec; Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Neutrogena, OGX, and Rogaine; BAND-AID, Carefree, Desitin, Johnson's, Listerine, o.b., and Stayfree; and ORSL, Clean & Clear, Versalie, Benylin, Daktarin, Imodium, Johnson's Baby, Johnson's Adult, Maui Moisture, Microlax, Motilium, Neosporin, Neostrata, Pepcid, Pulmicort, Regaine, Sudafed, and Visine/Vispring/Visclear brands. Kenvue Inc. was incorporated in 2022 and is headquartered in Summit, New Jersey.
Price above modeled range
Why: Dividends are a large share of earnings, so the cash paid to shareholders is the best guide to value.
The range depends on model assumptions and data; it is not a prediction or investment advice.
After signing in, return here and select “Add to watchlist”. Saving companies requires a verified email address.
Market price above modeled range
Showing the EPS-based Gordon proxy you selected on the company card, using 2.55% growth, 2.4% terminal growth and 9.2% discount. The range varies these assumptions slightly; it is illustrative, not investment advice.
Assumptions: growth 2.55%, discount rate 9.20%, terminal growth 2.40% (sector defaults). See a worked example.
Blended growth assumption: 2.5% (sector default 5.3%, own revenue history 0.1%, analyst revenue consensus 2.4%).
5-year outlook: relative outlook of about 9.6% a year (High confidence), anchored to a 7% market return and adjusted for how this company ranks against others. A ranking aid, not a prediction. See the full forecast.
Analyst consensus expects revenue growth of 2.4% a year; the growth assumption used is 2.6%.
Adjust assumptions
Show the recommended model instead
Why this model: Dividends are a large share of earnings, so the cash paid to shareholders is the best guide to value.
Compare models- Recommended: Dividend discount model — USD 18.62 (-3.5%)
-
EPS-based Gordon proxy
— USD 13.21 (-31.6%)
Not used: Treats all earnings as if paid out and ignores the cash kept for reinvestment, so it overstates value for companies that retain most profit.
-
DCF (trailing free cash flow)
— USD 16.20 (-16.1%)
Not used: Not chosen: Dividend discount model ranks ahead of it for this company.
-
FCFF (steady state)
— USD 16.07 (-16.8%)
Not used: Assumes only the long-run terminal growth rate from today, so it ignores the near-term growth expected.
-
EV/EBITDA (12x)
— USD 16.53 (-14.4%)
Not used: Used only when free cash flow is far below earnings even after averaging three years; a fixed 12x multiple also ignores sector differences.
-
Fade DCF (10-year growth fade)
— USD 16.20 (-16.1%)
Not used: An alternative growth path (fading over 10 years) shown for comparison; the automatic choice does not use it.
-
EV/Sales (Rule of 40)
— USD 34.19 (+77.1%)
Not used: Used only for technology and communication companies whose cash-flow value is far below the price.
| Bear USD 10.11 | -91.0% |
| Base USD 13.21 | -46.1% |
| Bull USD 15.49 | -24.6% |
Margin = (value − price) / value, so it is measured against the value and reads lower than the upside to value, which is measured against the price. Positive means the price is below that case.
Track record: see the methodology page for how this model has performed historically, including its limits. Treat it as a screen, not a forecast.
Price history and fair value
1 year price change: +24.43% · USD 19.31 · Market data through 30 Oct 2026 ; dashed line is today’s model base value (USD 13.21). The fair value is today’s estimate, not what the model said in the past.
Saved price history is current through 30 Oct 2026; last refreshed 06 Nov 2026 18:33 (1 hour, 6 minutes ago).
06 Nov 2025Range USD 15.33 – 19.8830 Oct 2026
Latest news
Headlines provided by EODHD. Articles may mention multiple companies and are not investment recommendations.
More detail: quality, peers, price history, dividends and financials
Quality score: 82 / 100
Five equal checks on reported history: profitability, cash generation, revenue growth, balance sheet and margins. It describes business quality, not whether the price is attractive.
| Profitability | 5 of 5 years profitable | 20 / 20 |
| Cash generation | free cash flow positive in 5 of 5 years | 20 / 20 |
| Growth | revenue +0.8% a year | 12 / 20 |
| Balance sheet | net debt 2.2x EBITDA | 10 / 20 |
| Margins | EBITDA margin 21% | 20 / 20 |
Peers in Consumer Staples
Same-sector companies with a valuation, most undervalued first. Compare the margin of safety, yield and quality score side by side.
| Company | Price | Margin of safety | P/E | P/B | Yield | Quality |
|---|---|---|---|---|---|---|
| KVUE (this company) | USD 19.31 | -3.7% | 22.0 | 3.7 | 6.4% | 82 |
| ORK.OL Orkla ASA | NOK 102.60 | 31.9% | 14.6 | 2.3 | 9.7% | 82 |
| WN.TO George Weston Limited | CAD 109.72 | 26.2% | 39.8 | 9.1 | 1.2% | 72 |
| KHC Kraft Heinz | USD 25.32 | 25.2% | – | 0.8 | 6.3% | 36 |
| CA.PA Carrefour SA | EUR 13.64 | 23.8% | 29.2 | 0.8 | 8.7% | 72 |
| ABF.L Associated British Foods plc | GBP 19.90 | 18.8% | 15.1 | 1.2 | 3.2% | 82 |
| ADM Archer Daniels Midland | USD 70.47 | 16.8% | 13.7 | 1.4 | 3.0% | 64 |
| AXFO.ST Axfood AB | SEK 283.80 | 7.9% | 25.0 | 8.2 | 3.1% | 70 |
| DLTR Dollar Tree | USD 137.94 | 0.3% | 16.3 | 7.7 | – | 72 |
| Peer median | 16.3 | 1.9 | ||||
Dividends
Paid in the last 12 months: USD 1.04 per share · yield 5.41% at the current price.
| Year | Dividends per share |
|---|---|
| 2026 (so far) | 0.836 |
| 2025 | 0.826 |
| 2024 | 0.810 |
| 2023 | 0.400 |
Trailing 12-month financials
TTM through 30 Sep 2026 · quarterly EODHD data · data downloaded 06 Nov 2026 13:10
| Revenue | USD 15,530,000,000 |
|---|---|
| EBITDA | USD 3,262,000,000 |
| EBIT | USD 2,693,000,000 |
| Net income | USD 1,690,000,000 |
| Free cash flow | USD 2,540,800,000 |
| Capital expenditures | USD 467,800,000 |
| Debt | USD 8,341,000,000 |
| Cash | USD 1,039,000,000 |
| Working capital | USD -277,000,000 |
| Shares outstanding | 1,926,000,000 |
| Reported dividends per share | USD 1.2368 |